ReviewSeminars in dialysis
Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.
Review in Seminars in dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.Scientific reports · 2025Trial
- Association between enteral carboxymethyllysine intake and daily glycemic variability in critically ill adults: A retrospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2025Article
- Vascular inflammation in chronic kidney disease: the role of uremic toxins in macrophage activation.Frontiers in cardiovascular medicine · 2025Review
- Post-translational modifications in kidney diseases and associated cardiovascular risk.Nature reviews. Nephrology · 2024Review
- Derivation and elimination of uremic toxins from kidney-gut axis.Frontiers in physiology · 2023Review
- Article
- The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.International journal of molecular sciences · 2022Review
- Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.Oxidative medicine and cellular longevity · 2021Review
- Gut-Derived Protein-Bound Uremic Toxins.Toxins · 2020Review
- Factors Associated With Change in Skin Autofluorescence, a Measure of Advanced Glycation End Products, in Persons Receiving Dialysis.Kidney international reports · 2020Article
- Serum advanced glycation end products are not associated with muscle strength in hemodialysis patients.European journal of clinical nutrition · 2019Article
- Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?The International journal of angiology : official publication of the International College of Angiology, Inc · 2017Review
- Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?Disease markers · 2017Article
- Uremic Toxicity of Advanced Glycation End Products in CKD.Journal of the American Society of Nephrology : JASN · 2016Review
- Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes.Frontiers in medicine · 2015Review
- Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?Current opinion in nephrology and hypertension · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
It has been nearly 100 years since the first published report of advanced glycation end products (AGEs) by the French chemist Maillard. Since then, our understanding of AGEs in diseased states has dramatically changed. Especially in the last 25 years, AGEs have been implicated in complications related to aging, neurodegenerative diseases, diabetes, and chronic kidney disease. Although AGE formation has been well characterized by both in vitro and in vivo studies, few prospective human studies exist demonstrating the role of AGEs in patients on chronic renal replacement therapy. As the prevalence of end-stage renal disease (ESRD) in the United States rises, it is essential to identify therapeutic strategies that either delay progression to ESRD or improve morbidity and mortality in this population. This article reviews the role of AGEs, especially those of dietary origin, in ESRD patients as well as potential therapeutic anti-AGE strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.